15 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
NVO Novo Nordisk A/S $47.64 $114.84B Buy
Article Searches
The New Generex: Unlocking The Value https://seekingalpha.com/article/4228973-new-generex-unlocking-value?source=feed_sector_healthcare Dec 18, 2018 - Merck collaboration on Phase II cancer trial against triple negative breast cancer and Shenzhen collaboration for Phase II cancer trial against prostate cancer.Buccal delivery system for insulin insid
Story Starting To Change For AEterna Zentaris https://seekingalpha.com/article/4231159-story-starting-change-aeterna-zentaris?source=feed_sector_healthcare Jan 03, 2019 - It has been a long road for AEterna Zentaris and their AGHD testing drug Macrilen. But management has been executing the correct moves to get the product to market.Strongbridge sold their U.S. and Can
What The Celgene Deal Means For The Biotech Sector https://seekingalpha.com/article/4231701-celgene-deal-means-biotech-sector?source=feed_sector_healthcare Jan 07, 2019 - On Jan. 3, pharma giant Bristol-Myers Squibb announced its intention to acquire Celgene, one of the largest biotech companies in the world, for $74 billion; the deal awaits shareholder approval.The bu
J&J raises US prices on around two dozen drugs https://www.cnbc.com/2019/01/11/jj-raises-us-prices-on-around-two-dozen-drugs.html Jan 11, 2019 - Johnson & Johnson raised U.S. prices on around two dozen prescription drugs on Thursday, including the psoriasis treatment Stelara, prostate cancer drug Zytiga and blood thinner Xarelto, all among its top-selling products.
Sanofi's Myeloma Candidate Meets Goal in Phase III Study http://www.zacks.com/stock/news/352133/sanofis-myeloma-candidate-meets-goal-in-phase-iii-study?cid=CS-ZC-FT-352133 Feb 05, 2019 - Sanofi's (SNY) late-stage candidate, isatuximab, achieves the primary endpoint in a pivotal study by prolonging progression free survival in patients with relapsed/refractory multiple myeloma.
Vanguard Health Care: A Good Place To Invest For The Future https://seekingalpha.com/article/4226233-vanguard-health-care-good-place-invest-future?source=feed_sector_healthcare Dec 04, 2018 - The increasing prevalence of a few diseases has caused the life expectancy in the United States to decline for the third straight year.One of these diseases is diabetes, which is a chronic condition l
Retirement: 2018 Performance Of The Future-Proof Portfolio For Young Investors https://seekingalpha.com/article/4234427-retirement-2018-performance-future-proof-portfolio-young-investors?source=feed_all_articles Jan 20, 2019 -
Fundsmith Equity Fund Annual Letter To Shareholders 2018 https://seekingalpha.com/article/4234913-fundsmith-equity-fund-annual-letter-shareholders-2018?source=feed Jan 23, 2019 -
Tracking Ken Fisher's Fisher Asset Management Portfolio - Q4 2018 Update https://seekingalpha.com/article/4236060-tracking-ken-fishers-fisher-asset-management-portfolio-q4-2018-update?source=feed_all_articles Jan 28, 2019 - Fisher’s 13F portfolio value decreased from $82.37B to $73.22B in Q4 2018.Visa Inc., Amazon.com, Apple Inc., Microsoft, and Pfizer are the largest five individual stock positions.Fisher has substantia
Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat http://www.zacks.com/stock/news/351653/novo-nordisk-nvo-q4-earnings-miss-estimates-revenues-beat?cid=CS-ZC-FT-351653 Feb 01, 2019 - Novo Nordisk (NVO) fourth-quarter 2018 results mainly benefit from strong performance by Ozempic.

Pages: 12

Page 1

Related Companies

Name Exchange Price Mkt Cap
LLY Eli Lilly and Company NYSE $105.71 $113.53B
ABT Abbott Laboratories NYSE $67.67 $118.71B
SNY Sanofi NYSE $43.75 $109.14B
BMY Bristol-Myers Squibb Company NYSE $61.3 $100.03B
GSK GlaxoSmithKline PLC NYSE $39.21 $97.25B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for Novo Nordisk A/S
NVO - Google Finance https://www.google.com/finance?q=NVO Industry related info and international coverage Summary News
NVO - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=NVO Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options